Show Summary Details
Page of

Engaging patients in therapeutic development 

Engaging patients in therapeutic development
Engaging patients in therapeutic development

Emil Kakkis

, and Max Bronstein

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 02 March 2021

Engagement of patients during the development of new treatments has evolved rapidly in the last decade. No longer should patients be viewed as passive subjects of research: they should be active participants in a more open and ambitious ecosystem of academic investigators, companies, and government entities. Enhanced engagement of patients throughout the development process provides important benefits for the introduction of useful and effective drugs by changing the understanding of the disease, the measurement of the disease during treatment, and the interpretation of benefit-risk. This system is critical for the discovery, study, development, regulation, delivery, and use of innovative therapies.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.